当前位置: X-MOL 学术Pediatr. Allergy Immunol. Pulmonol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Current State and Future of Biologic Therapies in the Treatment of Asthma in Children.
Pediatric Allergy, Immunology, and Pulmonology ( IF 0.9 ) Pub Date : 2018-10-05 , DOI: 10.1089/ped.2018.0901
Elissa M Abrams 1 , Allan B Becker 1 , Stanley J Szefler 2
Affiliation  

There is increasing recognition of phenotypic variability in pediatric asthma, providing the opportunity for a more personalized approach to therapy. Increasingly biologic therapies, in particular those targeting the "allergic" (or T helper 2) pathway, are being considered for children with severe asthma. However, there is a great deal of variability in the extent these biologic therapies have been studied in children, as well as efficacy of results thus far. The goal of this article is to review the mechanism of action, efficacy, and potential predictive and monitoring biomarkers of the biologic medications focusing on the pediatric population, in an effort to establish a more personalized approach to asthma in the pediatric population for the 21st century.

中文翻译:

儿童哮喘的生物疗法的现状和未来。

小儿哮喘的表型变异性得到了越来越多的认可,为更个性化的治疗方法提供了机会。对于患有严重哮喘的儿童,正在考虑采用越来越多的生物疗法,尤其是针对“过敏性”(或T辅助2)途径的生物疗法。然而,在儿童中研究这些生物疗法的程度以及迄今为止的结果有效性存在很大差异。本文的目的是回顾针对小儿科人群的生物药物的作用机理,功效以及潜在的预测和监测生物标志物,以期为21世纪的小儿科人群建立更加个性化的哮喘治疗方法。
更新日期:2019-11-01
down
wechat
bug